Pharmaceutical Industry in the
Canton of Zurich
262 companies in Pharmaceutical Industry based in the Canton of Zurich — name and year of registration from the commercial register.
50 of 262 companies
Molecular Partners AG
Since 2004 · 101–500 empl.4.9(11)
The company develops innovative therapeutic compounds, in particular DARPins, for diseases with high unmet medical need, with a focus on ophthalmology and oncology.
Vifor Pharma Management AG
Since 2008 · 101–500 empl.4.4(8)
The core activity of CSL Vifor is the development, manufacture and marketing of pharmaceutical products, particularly in the areas of iron deficiency, nephrology and cardiorenal therapies. The company focuses on the development of innovative therapies for rare diseases and unmet medical needs, positioning itself as a global partner for strategic partnerships and in-licensing.
Biomed AG
Since 1951 · 21–50 empl.4.8(6)
Biomed AG is an independent trading company for prescription and over-the-counter pharmaceutical products and supplements. It markets and distributes a broad portfolio including mineral supplements (magnesium, iron, zinc), products for respiratory infections, weight-management preparations, vitamins, and remedies for insect stings and denture care. The company works with physicians, hospitals, pharmacies and drug stores and participates in partner research projects but does not carry out its own research.
LimmaTech Biologics AG
Since 2015 · 51–100 empl.4.8(4)
The core activity of LimmaTech Biologics AG is the development and manufacture of vaccines and other biotechnological products, particularly in the field of infectious diseases. The company focuses on the development of a proprietary vaccine platform and has a pipeline of products in various stages of development.
Ophtapharm AG
Since 2003 · 101–500 empl.4.8(4)
The core activity of Ophtapharm AG is the manufacture of sterile eye and ear products, particularly liquid and semi-solid dosage forms such as drops, suspensions, gels and ointments. The company offers contract manufacturing services, where it develops, manufactures and packages products for its customers. The products are mainly sold on the American market and distributed worldwide by the company's customers.
Gesundheitszentrum Uster GmbH
Since 2017 · 11–20 empl.4.1(70)
Gesundheitszentrum Uster GmbH is a group medical practice offering both conventional and complementary medical services, including general internal medicine, paediatric care and general surgery. The practice includes on-site facilities such as a laboratory, an outpatient operating room, an in-practice dispensary and diagnostic equipment including ultrasound, digital X-ray and ECG.
Kyon Biotech AG
Since 2009 · 11–20 empl.3.6(7)
Kyon Biotech AG supplies orthopedic implants, surgical instruments and training to the veterinary market. Its offerings include veterinary total hip replacement (THR), tibial tuberosity advancement (TTA), tibial plateau leveling osteotomy (TPLO) systems, plating solutions and related services.
Mabylon AG
Since 2011 · 11–20 empl.4.7(3)
The core activity of Mabylon AG is research and development in the field of biotechnology.
Takeda Pharma AG
Since 1986 · 101–500 empl.3.5(20)
Takeda Pharma AG is a pharmaceutical company that researches, develops, manufactures and commercializes medicines. Its stated areas of focus include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Baxter AG
Since 1976 · 101–500 empl.5.0(2)
Baxter AG develops and supplies medical devices, medicines and clinical nutrition products for hospital care, renal treatment, surgical care and nutritional support.
Stallergenes AG
Since 1996 · 21–50 empl.5.0(3)
The core activity of Stallergenes Greer is the manufacture of allergen extracts for allergy immunotherapy (AIT) and the provision of solutions for allergy management, including diagnosis, treatment and prevention of allergies.
InterAx Biotech AG
Since 2016 · 11–20 empl.5.0(2)
The core activity of InterAx Biotech AG is the development of solutions in the field of computer-aided chemistry and systems biology, particularly in the context of GPCR signaling pathways and medicinal chemistry. The company combines expertise in computer science, biology, chemistry, and pharmacy to develop innovative approaches for the development of drugs and therapies.
Medinova AG
Since 1945 · 51–100 empl.
The core activity of Medinova AG is the marketing and distribution of pharmaceutical products, in particular prescription-only medicines (Rx) and over-the-counter products (OTC/medical devices), with the goal of improving people's quality of life.
Bayer (Schweiz) AG
Since 1954 · 101–500 empl.
Bayer (Schweiz) AG is part of the global Bayer group and operates in healthcare and agriculture. The company develops and markets pharmaceuticals, consumer health products, and solutions for crop protection, seeds, and agricultural technology.
IMCD Switzerland AG
Since 1957 · 21–50 empl.
IMCD is a distributor and service provider for the chemical and pharmaceutical industries. The company's core activity is to create value for its business partners by offering a wide range of services, including distribution, marketing, technical support, and formulation. IMCD supports its customers in achieving their sustainability goals and provides consulting and technical support in implementing new solutions. The company has a global network and supports its customers across various industries.
Galepharm AG
Since 1959 · 11–20 empl.
The core activity of Galepharm AG is the development, manufacture and marketing of prescription niche products, in particular medicines that are no longer produced by other companies due to low demand, but are essential for many patients. The company specializes in providing established medicines and works with international partners to do so.
Schweizer Blisterzentrum AG
Since 1986 · 11–20 empl.
The Swiss Blister Centre is a company specializing in the blister packaging of medications. The core activity of the company is to manufacture individually portioned medications for patients to increase safety when taking medications. The company offers a modern production facility where medications are packaged to enable patients to receive safe and individualized medication administration.
Astellas Pharma AG
Since 1987 · 21–50 empl.
The core activity of Astellas Pharma AG is the development, manufacture and marketing of pharmaceuticals, particularly in the therapeutic areas of oncology, urology, nephrology and transplantation. The company is also engaged in research and development of new medicines and supports medical training and clinical studies.
Virbac (Switzerland) AG
Since 1988 · 101–500 empl.
The core activity of Virbac is the development and distribution of products for animal health, particularly for the prevention and treatment of diseases in animals, as well as promoting animal welfare and sustainable animal husbandry.
ALK-Abelló AG
Since 1990 · 101–500 empl.
The core activity of the company ALK is the development, manufacture and marketing of products for specific immunotherapy, in particular for the prevention, diagnosis and treatment of allergies, including allergic rhinitis and allergic asthma.
Cedem AG
Since 1991 · 21–50 empl.
The core activity of CEDEM AG is the development, manufacture and marketing of dietary supplements, vitamins and minerals that meet traditional Swiss quality standards. The company offers a wide range of products tailored to the specific health needs of women, men and children, including products for healthy aging and longevity.
Almirall AG
Since 1992 · 101–500 empl.
The core activity of Almirall is the development, manufacture and marketing of pharmaceuticals, particularly in the field of dermatology and skin health. The company focuses on researching and developing innovative medical solutions for the treatment of skin diseases and other health issues.
A. Menarini GmbH
Since 1996 · 21–50 empl.
The core activity of A. Menarini GmbH is the development, manufacture and marketing of pharmaceuticals, particularly medications for the basic care of patients, which are mainly prescribed by general practitioners and specialists. The products cover various therapeutic areas, including cardiology, infectiology, allergology, diabetology, rheumatology/pain management and medical aesthetics.
Daiichi Sankyo (Schweiz) AG
Since 1998 · 21–50 empl.
Daiichi Sankyo is a pharmaceutical company specializing in the development, production, and distribution of pharmaceutical products. The company's core activity lies in the research, development, and provision of medicines and health products, particularly in the field of antithrombotics. The company also offers additional services such as digital solutions for communication between doctors and patients, as well as training platforms for healthcare professionals.
Target BioScience AG
Since 2000 · 1–10 empl.
The core activity of Target BioScience AG is to provide services in the field of regulatory affairs for the pharmaceutical and biotechnology industry in Switzerland. This includes in particular: Regulatory Affairs: Submission and maintenance of marketing authorization for medicinal products with Swissmedic; Marketing Authorization Holding: Services as holder of the marketing authorization; Quality Management: Consulting and services in the field of quality management; RP Provision: Services as responsible person (Responsible Person); Market Access: Services in the field of market access and price setting. The company thus supports pharmaceutical and biotech companies in complying with regulatory requirements in Switzerland and helps them to bring and maintain their products on the market.
Roche Glycart AG
Since 2000 · 11–20 empl.
Roche Glycart AG is part of Roche and is engaged in pharmaceutical and diagnostic solutions. The company focuses on medicines, diagnostics, digital products, and related services across the patient journey.
Lipal Biochemicals AG
Since 2000 · 1–10 empl.
The core activity of Lipal Biochemicals is the development, manufacture and marketing of biochemical products.
GE Healthcare AG
Since 2000 · 101–500 empl.
GE Healthcare AG is a medical technology company that provides imaging systems and modalities including ultrasound, CT, MRI, mammography and molecular imaging. It also supplies contrast media and nuclear imaging agents, patient monitoring and perioperative solutions, healthcare IT and digital services, alongside lifecycle services such as maintenance, predictive services, cybersecurity and financing.
OrPha Swiss GmbH
Since 2003 · 11–20 empl.
The core activity of OrPha Swiss is the development, manufacture and marketing of medicines for rare diseases (Orphan Diseases) and niche areas, particularly in the fields of pulmonary hypertension, infectiology and intensive and emergency medicine.
Biotech Concepts GmbH
Since 2005 · 1–10 empl.
Biotech Concepts GmbH conducts antibiotic research and develops biotechnological production processes. It provides consulting and project management for biotech and pharmaceutical projects, process development (including biocatalysis and fermentation), technology transfer, training and SOP writing, supports API production such as cephalosporins and 7‑ACA, and offers a low‑budget programmable lab/pilot automation system called ARMin.
Eisai Pharma AG
Since 2005 · 11–20 empl.
Eisai Pharma AG is a research and development-oriented pharmaceutical company specializing in the research, development, and distribution of products in the fields of neurology and oncology. The company's core activity is the development and provision of innovative treatment options for patients with severe illnesses, particularly in the fields of neurology and oncology.
CONARTIX GmbH
Since 2006 · 1–10 empl.
The core activity of Conartix Health AG is the development, manufacture and marketing of nature-based health products and dietary supplements, particularly based on plant-based substances and prebiotics, with the aim of promoting human health and quality of life.
Vaccentis AG
Since 2006 · 11–20 empl.
The core activity of Vaccentis AG is the development of tumor vaccines, particularly through the use of the individualized precision immunotherapy platform AIPI (ALL INDIVIDUALIZED PRECISION IMMUNOTHERAPY TUMOUR VACCINE TECHNOLOGY PLATFORM).
Philochem AG
Since 2006 · 11–20 empl.
The core activity of Philochem is the development and research of bioactive compounds for cancer treatment, particularly in the areas of Target Discovery, Ligand Discovery and small molecule therapeutics. The company focuses on developing compounds that target the site of the disease while protecting healthy tissue. The company's products include various radiopharmaceuticals for imaging and therapy of cancer, such as 68Ga-OncoFAP, 177Lu-OncoFAP and 68Ga-OncoCAIX.
Redbiotec AG
Since 2006 · 11–20 empl.
The core activity of Redbiotec AG is the development and production of key proteins and genetic materials for the biopharmaceutical and food industries. The company focuses on the research and development of therapeutic bacteria for the treatment of cancer and genetic diseases.
Takeda Pharmaceuticals International AG
Since 2007 · 51–100 empl.
Takeda Pharmaceuticals International AG is the regional corporate office of Takeda and serves as the group's regional headquarters. It supports and represents the company’s pharmaceutical activities, including research and development, manufacturing and product distribution.
Herb-pharma AG
Since 2008 · 1–10 empl.
The core activity of Herb-Pharma is the development, manufacture and marketing of cosmetic products, dietary supplements and pharmaceuticals based on natural ingredients and biotechnological products. The company focuses particularly on skin care and develops innovative products based on scientific findings and sustainable natural resources.
steinberg pharma ag
Since 2008 · 1–10 empl.
The core activity of Steinberg Pharma AG is the development, production and distribution of complementary medical products, pharmaceuticals, medical devices, products for the podology specialist trade, as well as dietary supplements. In addition, the company offers services in the areas of registration, dossier maintenance and consulting.
Virometix AG
Since 2009 · 11–20 empl.
The core activity of Virometix AG is the development of pharmaceuticals and therapeutics, particularly in the fields of oncology and virology, using live biotherapeutics and other innovative technologies.
NORIS PHARMA AG
Since 2011 · 1–10 empl.
NORIS PHARMA AG develops proprietary OTC products, medical devices and dietary supplements and provides consultancy services for the medical, pharmaceutical and healthcare sectors. The company supports the full product development and launch process, including market analysis, formulation proposals, supplier selection, production oversight and product registration.
MedComms Experts GmbH
Since 2012 · 11–20 empl.
The company provides services in the field of medical communication, particularly for pharmaceutical and biotechnology companies. The core activity includes the development of strategic communication concepts, the creation of scientific content, the implementation of medical training and the creation of educational materials for healthcare professionals. The company supports its customers in communicating complex scientific information and helps them achieve their goals in the field of medical communication.
Axanton Technology GmbH
Since 2013 · 1–10 empl.
Axanton Technology GmbH develops MEMS (Molecules Establishing Membrane Signaling), a technology for producing therapeutic biomolecules that target chemically modified membrane protein sequences to restore membrane protein homeostasis. The company conducts research and preclinical development of candidates such as A‑144 and holds patented technology for MEMS production.
SENTISS AG
Since 2013 · 21–50 empl.
Sentiss Pharma is a pharmaceutical company specializing in the development and manufacture of medicines, particularly in the field of ophthalmology and special products. The company's core activity includes research and development of new medicines, production of high-quality products, and provision of health solutions for customers worldwide. In contrast, Inzox is a financial services provider specializing in providing financial solutions for companies and private individuals. The company's core activity includes providing financial advisory services, managing assets, and providing financial products.
SLC Bellevue GmbH
Since 2013 · 11–20 empl.
The core activity of SLC Bellevue GmbH - LUXES COSMETICS is the development, manufacture and marketing of natural cosmetics products, particularly skin care products, under the LUXES brand.
Otsuka Pharmaceutical (Switzerland) GmbH
Since 2013 · 11–20 empl.
The core activity of Otsuka Pharmaceutical Europe Ltd. is the development, manufacture and marketing of pharmaceutical products and nutritional supplements (Nutraceuticals) to improve the health and well-being of people worldwide.
Swiss Bioscience GmbH
Since 2014 · 11–20 empl.
The core activity of Swiss Bioscience GmbH is the development and production of pharmaceutical-grade stem cells, particularly human adipose tissue-derived stem cells (hADSCs), under cGMP conditions. The company offers services such as stem cell banking, research and development, and focuses on the application of stem cells in regenerative medicine, particularly for the treatment of age-related diseases.
Alvotech Swiss AG
Since 2014 · 21–50 empl.
Alvotech Swiss AG develops and manufactures biosimilars, with a pipeline focused on monoclonal antibodies and other biologic medicines. The company follows a vertically integrated approach from R&D through drug product manufacturing and collaborates with commercial partners for market access.
NovaGo Therapeutics AG
Since 2015 · 11–20 empl.
The core activity of Neurimmune (or NovaGo) is the development of therapeutic antibodies for the treatment of neurodegenerative and other diseases, particularly Alzheimer's, Parkinson's, tauopathies, and amyotrophic lateral sclerosis. The company focuses on the discovery, development, and clinical testing of antibody-based medications.
Dr. Andres Pharma AG
Since 2015 · 11–20 empl.
The core activity of Dr. Andres Pharma AG is the development and manufacture of natural products based on biologically cultivated medicinal plants, particularly for the treatment of rheumatic complaints and accident and sports injuries.
Advanz Pharma Specialty Medicine Switzerland GmbH
Since 2015 · 1–10 empl.
Advanz Pharma Specialty Medicine Switzerland GmbH is a pharmaceutical company that commercialises specialty, hospital and rare disease medicines. Its portfolio includes biosimilars, specialty generics and originator brands, and it works with biopharma and pharmaceutical development partners.
Pharmaceutical Industry in the Canton of Zurich
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Pharmaceutical Industry in other places
By canton